# T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

> **NCT05435014** · PHASE1,PHASE2 · SUSPENDED · sponsor: **T-ACE Medical Co., Ltd** · enrollment: 82 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** T-ACE Oil
- **DRUG:** Lipiodol

## Key facts

- **NCT ID:** NCT05435014
- **Lead sponsor:** T-ACE Medical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-09-13
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 82 (ESTIMATED)
- **Why stopped:** The study was suspended in Taiwan following regulatory authority decision. The overall study under U.S. IND remains active.
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435014, "T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05435014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*